Receptor Signalling in Peptide Research: Agonists, Antagonists and Pathway Selectivity
The short answer
Many peptides communicate with cells by binding to receptors. An agonist can activate a receptor, while an antagonist can reduce or block activation by another ligand. Partial agonists, inverse agonists and allosteric modulators add further complexity.
These labels describe pharmacological behaviour under defined experimental conditions. They do not, on their own, establish a whole-organism outcome, clinical benefit, safety profile or equivalence between two materials that target the same receptor.
From binding to signalling
A receptor is a protein that can recognize compatible signalling molecules. Binding may change the receptor’s conformation and initiate events inside the cell. G-protein-coupled receptors, for example, can engage G proteins, arrestins and other effectors. The measured response depends on the receptor, cell type, assay system, ligand concentration, timing and available signalling machinery.
Binding and activation are related but distinct. A material may bind strongly without producing a large response, or it may produce substantial signalling despite lower apparent affinity in a particular system.
Agonists, antagonists and partial responses
A full agonist can produce the reference system’s maximal response under the conditions tested. A partial agonist activates the receptor but produces a lower maximum in that system. An antagonist occupies or otherwise influences the receptor without producing the same activating response and can reduce the action of an agonist.
These classifications are not completely independent of the model. Receptor density and signal amplification can make the same ligand appear more or less efficacious in different cell systems. That is one reason a single assay should not be treated as a complete biological profile.
Affinity, potency and efficacy are not interchangeable
Affinity describes how favourably a ligand binds to a receptor. Potency describes how much material is required to produce a defined response in a particular assay. Efficacy describes the capacity of the ligand–receptor complex to generate a response.
A lower numerical concentration in one assay does not automatically mean a material is more effective in an organism. Potency can change with assay design, receptor expression, exposure time and the endpoint selected.
Selectivity and pathway bias
Selectivity asks whether a ligand acts more strongly at one target than at others. It is usually relative, not absolute. Results also depend on which targets were tested and at what concentrations.
Some ligands can favour one downstream pathway over another through the same receptor. This is often called biased signalling or functional selectivity. It can be scientifically useful, but claims of bias require appropriate reference ligands, multiple pathways and careful quantitative analysis. A difference observed in an engineered cell line may not persist in native tissue.
Why experimental context matters
Cell assays can identify receptor activity and compare signalling patterns. Tissue and animal studies add biological context but introduce species differences. Human studies can evaluate outcomes in people, yet their conclusions still apply to the exact material, formulation, exposure and population studied.
Mechanistic evidence provides a rationale for further research. It should not be presented as proof of a clinical effect.
Questions to ask when reading receptor research
- Which receptor and species were studied?
- Was the experiment a binding assay or a functional signalling assay?
- Which cells, tissues and downstream pathways were measured?
- What reference agonist or antagonist was used?
- Were selectivity and off-target activity examined?
- Has the finding been reproduced outside the original assay system?
Key points
- Binding does not necessarily equal receptor activation.
- Affinity, potency and efficacy describe different properties.
- A ligand’s apparent behaviour can change with receptor density and assay design.
- Pathway selectivity is a testable pharmacological claim, not a guarantee of a particular outcome.
- Mechanistic results do not establish clinical benefit, safety or product equivalence.
What this article does not establish
This article does not establish the identity, purity, safety, effectiveness or regulatory status of any AURAPEP product and does not recommend a compound for personal use.
References
- Sum CS, et al. Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization. Assay Guidance Manual. 2019. https://www.ncbi.nlm.nih.gov/books/NBK549462/
- Hoare SRJ, et al. Biosensor Assays for Measuring the Kinetics of G-Protein and Arrestin Signaling in Live Cells. Assay Guidance Manual. 2021. https://www.ncbi.nlm.nih.gov/books/NBK574243/
- Wang T, et al. Measurement of β-Arrestin Recruitment for GPCR Targets. Assay Guidance Manual. 2017. https://www.ncbi.nlm.nih.gov/books/NBK464634/